VivoSim Labs, INC. (VIVS) stock
VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$0.12−0.00 (-2.91%)
Close on Nov 17, 2026Market cap $383.64KP/E –Yield –
VivoSim Labs ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
VivoSim Labs's ebitda for the twelve months ending Jun 30, 2026 was -$11.14M. For fiscal 2026 it was -$11.27M. The highest annual figure on record is -$1.12M in fiscal 2010.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$11.27M | – |
| FY2025 | Mar 31, 2025 | -$12.35M | – |
| FY2024 | Mar 31, 2024 | -$14.81M | – |
| FY2023 | Mar 31, 2023 | -$17.44M | – |
| FY2022 | Mar 31, 2022 | -$11.34M | – |
| FY2021 | Mar 31, 2021 | -$16.79M | – |
| FY2020 | Mar 31, 2020 | -$20.33M | – |
| FY2019 | Mar 31, 2019 | -$26.29M | – |
| FY2018 | Mar 31, 2018 | -$34.00M | – |
| FY2017 | Mar 31, 2017 | -$37.43M | – |
| FY2016 | Mar 31, 2016 | -$37.83M | – |
| FY2015 | Mar 31, 2015 | -$29.83M | – |
| FY2012 | Dec 31, 2012 | -$9.12M | – |
| FY2011 | Dec 31, 2011 | -$2.24M | – |
| FY2010 | Dec 31, 2010 | -$1.12M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$2.72M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$3.14M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$2.70M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$2.58M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$2.85M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$3.09M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$3.40M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$2.54M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$3.32M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$3.03M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$3.61M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$4.04M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$4.13M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$7.72M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$3.23M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$3.30M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$3.19M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$1.87M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$3.46M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$3.47M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$2.53M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$2.58M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$2.48M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$8.95M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$2.78M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$2.89M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$4.48M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$6.65M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$6.32M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$7.01M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$6.27M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$5.73M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$7.29M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$7.28M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$7.59M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$9.26M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$9.87M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$10.36M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -$9.31M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | -$9.23M | – |
See a number that looks wrong?